Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Study Strengthens Evidence of Link Between Liver Cancer and Diabetes

March 2, 2005
By James L. Abbruzzese, MD, FACP
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 14 No 3
Volume 14
Issue 3

This special “annual highlights” supplement to Oncology News International (ONI)is a compilation of selected news on important advances in the management ofgastrointestinal cancers over the past year, as reported in ONI. Guest Editor, Dr.James L. Abbruzzese, comments on the reports included herein and discussesdevelopments in the clinical management of GI cancers, with a look at the impactof targeted agents with cytotoxic chemotherapy, first-line and adjuvant therapies foradvanced disease, and the role of statins and COX-2 inhibitors in prevention.

SEATTLE-Diabetics may facethree times the risk of liver cancer,according to data from a new study. Anumber of epidemiological studieshave "suggested a relationship betweensome cancer types and diabetes, andthe most consistent results have beenfor cancers of the liver and the pancreas,"said Marie-Claude Rousseau, PhD,a postdoctoral fellow, in the Departmentof Social and Preventive Medicine,at the University of MontrealFaculty of Medicine."Some biological mechanisms havebeen proposed to suggest how diabetesaffects the risk of cancer, but to thisday, they remain only hypothetical. Soclearly, the question of whether cancerrisk is associated with diabetes isstill open," Dr. Rousseau said. Shepresented the findings at the AmericanAssociation for Cancer ResearchThird Annual International Conferenceon Frontiers in Cancer PreventionResearch (abstract 195).The investigators used data collectedfrom a study conducted in Montreal during the 1980s designed to addressworkplace factors and the risk ofcancer among men. The large population-based multisite case-controlstudy included information about priordiagnosis for diabetes, age at diagnosis,and medication use for diabetes.The study sample was comprisedof 3,288 male patients who had beenrecently diagnosed with cancer and509 healthy controls.Patients with diabetes also providedinformation about their usualheight and weight and lifestyle factors."These are important to consider whenstudying diabetes and cancer risk,"Dr. Rousseau said.The investigative team analyzed theassociation between diabetes and 12different types of cancer. "Out of the20 different cancer types that weredocumented in this study, our analysesfocused on 12 types for which thenumber of patients was large enoughto provide sufficient statistical powerfor the analyses," she explained.Study ResultsAfter adjusting for body mass indexand other covariates, the risk ofliver cancer was found to be elevatedamong men who reported a prior diagnosisof diabetes. The adjusted oddsratio (OR) was 3.1. The proportion ofdiabetics was 24% among liver cancerpatients, while only 8% of controlsreported having diabetes."These estimates were slightly higherwhen we used a more stringent definitionof diabetes," Dr. Rousseau said.This definition included only thosesubjects who were taking medication.The adjusted odds ratio for liver cancerfor this subgroup was 3.9.An association was observed withpancreatic cancer, mostly due to recentlydiagnosed diabetes. "This maysuggest that diabetes was a result of thepancreatic cancer rather than the opposite,"Dr. Rousseau said.The researchers did not observe anyassociation with other cancers studied,including melanoma, non-Hodgkin's lymphoma, and cancers ofthe esophagus, stomach, colon,rectum, lung, prostate, bladder, andkidney."While this was not the first studyto examine the link between cancerand diabetes, key features of our studieswere that we could assess the risk ofseveral different cancer types in thesame population and that the patientswere newly diagnosed," Dr. Rousseausaid. "Also, we had information thatallowed us to adjust for important factors,such as body mass index, smoking,and alcohol consumption. In conclusion,our study is strengthening theevidence of a link between diabetesand liver cancer."Dr. Rousseau's colleagues in thestudy were Jack Siemiatycki, PhD, Universityof Montreal, and Marie-EliseParent, PhD, INRS-Institut Armand-Frappier, Laval, Quebec.

Articles in this issue

Smoking Speeds Progression of Pancreas Ca
Alcohol, Obesity, and Smoking Risk Factors for HCC
Eloxatin Receives FDA Indication for Use in Adjuvant Treatment of Stage III Colon Cancer
Adding Bevacizumab Improves Response to Oxaliplatin Regimens
Capecitabine Promises Convenience, Efficacy in LARC, Five Studies Show
Avastin Enhances FOLFOX Efficacy

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
The requirement for morphological dysplasia may become less important in the presence of molecular drivers of myelodysplastic syndrome.
Related Content

Dato-DXd Increases Intracranial Responses/PFS in NSCLC With Brain Mets

Dato-DXd Increases Intracranial Responses/PFS in NSCLC With Brain Mets

Kyle Doherty
September 9th 2025
Article

Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 9th 2025
Podcast

The safety and tolerability of nivolumab/chemotherapy in non–small cell lung cancer were manageable and consistent with its profiles in other clinical scenarios.

Adjuvant Nivolumab/Chemo Reduces Recurrence Risk in Resected NSCLC

Roman Fabbricatore
September 9th 2025
Article

Man Up? The Truth About Men's Health After Cancer

Man Up? The Truth About Men's Health After Cancer

Daniel C. McFarland, DO;Christian J. Nelson, PhD
September 9th 2025
Podcast

Ivonescimab plus chemotherapy following progression after a third-generation TKI showed consistent efficacy across EGFR-mutated NSCLC subgroups.

Ivonescimab/Chemo After TKI Progression Improves PFS in EGFR-Mutated NSCLC

Ashley Chan
September 9th 2025
Article

The overall safety profile of pirtobrutinib was consistent with previously reported trials across various CLL and SLL settings.

Pirtobrutinib Improves PFS in Treatment-Naïve CLL/SLL Without 17p Deletions

Tim Cortese
September 9th 2025
Article
Related Content

Dato-DXd Increases Intracranial Responses/PFS in NSCLC With Brain Mets

Dato-DXd Increases Intracranial Responses/PFS in NSCLC With Brain Mets

Kyle Doherty
September 9th 2025
Article

Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 9th 2025
Podcast

The safety and tolerability of nivolumab/chemotherapy in non–small cell lung cancer were manageable and consistent with its profiles in other clinical scenarios.

Adjuvant Nivolumab/Chemo Reduces Recurrence Risk in Resected NSCLC

Roman Fabbricatore
September 9th 2025
Article

Man Up? The Truth About Men's Health After Cancer

Man Up? The Truth About Men's Health After Cancer

Daniel C. McFarland, DO;Christian J. Nelson, PhD
September 9th 2025
Podcast

Ivonescimab plus chemotherapy following progression after a third-generation TKI showed consistent efficacy across EGFR-mutated NSCLC subgroups.

Ivonescimab/Chemo After TKI Progression Improves PFS in EGFR-Mutated NSCLC

Ashley Chan
September 9th 2025
Article

The overall safety profile of pirtobrutinib was consistent with previously reported trials across various CLL and SLL settings.

Pirtobrutinib Improves PFS in Treatment-Naïve CLL/SLL Without 17p Deletions

Tim Cortese
September 9th 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.